ASCO 2024 | postMONARCH: abemaciclib with fulvestrant in pretreated HR+/HER2- breast cancer

Kevin Kalinsky • 2 Jun 2024

ASCO 2024

postMONARCH

Kevin Kalinsky, MD, MS, Winship Cancer Institute, Atlanta, GA, discusses results from the Phase III postMONARCH trial (NCT05169567) of abemaciclib plus fulvestrant in patients with HR+/HER2- advanced breast cancer (ABC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) and endocrine therapy (ET). Abemaciclib and fulvestrant significantly improved progression-free survival (PFS) compared to placebo plus fulvestrant. Dr Kalinsky additionally highlights positive data from a subgroup analyses from the trial. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Employment – EQRx (I); GRAIL (I)
Stock and Other Ownership Interests – EQRx (I); GRAIL (I)
Consulting or Advisory Role – 4D Pharma; AstraZeneca; Cullinan Oncology; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; eFFECTOR Therapeutics; Genentech/Roche; immunomedics; Lilly; Menarini Silicon Biosystems; Merck; mersana; Myovant Sciences; Novartis; Oncosec; Prelude Therapeutics; Puma Biotechnology; RayzeBio; RayzeBio; Seagen; Takeda
Research Funding – Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)
Other Relationship – Genentech; Immunomedics